Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 1;36(6):443-449.
doi: 10.1097/QCO.0000000000000972. Epub 2023 Sep 19.

Duration of antifungal treatment in mold infection: when is enough?

Vera Portillo  1 , Dionysios Neofytos
Affiliations
Review

Duration of antifungal treatment in mold infection: when is enough?

Vera Portillo et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: Although invasive mold infections (IMI) are a major complication in high-risk populations, treatment duration has not yet been well defined.

Recent findings: Guidelines suggest documenting clinical/radiological resolution and immunological recovery before stopping antifungal treatment, after a minimum duration of treatment of 3 months for invasive pulmonary aspergillosis, while longer (up to 6 months) duration is proposed for the treatment of invasive mucormycosis. However, data on and definitions of clinical/radiological resolution and immune recovery remain scarce. Limited real-life data suggest that often much longer courses of treatment are given, generally in the context of continuous immunosuppression, occasionally defined as secondary prophylaxis. However, clearcut definition and distinction of secondary prophylaxis from antifungal treatment remain to be defined.

Summary: Decisions to stop antifungal treatment are based on poorly defined treatment responses and immune reconstitution and experts' opinions. More evidence is needed to determine the optimal duration of treatment of IMI. Well designed, easy to use, and realistic algorithms to help clinicians decide when to stop antifungal treatment are urgently needed.

PubMed Disclaimer

References

    1. Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1–60.
    1. Brunel AS, Wójtowicz A, Lamoth F, et al. Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. Haematologica 2018; 103:e527–e530.
    1. Roth RS, Masouridi-Levrat S, Chalandon Y, et al. Invasive mold infections in allogeneic hematopoietic cell transplant recipients in 2020: have we made enough progress? Open Forum Infect Dis 2021; 9:ofab596.
    1. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091–1100.
    1. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068–1075.

Substances